Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes

Leukemia

Volumn 28, Issue 11, 2014, Pages 2241-2244

  Poloni, A ^a   Maurizi, G ^a   Mattiucci, D ^a   Amatori, S ^b   Fogliardi, B ^b   Costantini, B ^a   Mariani, M ^a   Mancini, S ^a   Olivieri, A ^a   Fanelli, M ^b   Leoni, P ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CDKN2B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2B;

ADOLESCENT; ADULT; AGED; DNA METHYLATION; FEMALE; GENETICS; HUMAN; MALE; MESENCHYMAL STROMA CELL; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; FEMALE; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; YOUNG ADULT;

EID: 84922332837     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.197     Document Type: Letter

References (15)

1. Mufti GJ. Pathobiology, classification, and diagnosis of myelodysplastic syndromes. Best Pract Res Clin Haematol 2004; 17: 543–557. DOI: 10.1016/S1521-6926(04)00073-8
2. Nimer SD. Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol 2008; 87: 777–795. DOI: 10.1007/s00277-008-0502-z
3. Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndromes. Exp Hematol 2007; 35: 1739–1746. DOI: 10.1016/j.exphem.2007.09.007
4. Tauro S, Hepburn MD, Peddie CM, Bowen DT, Pippard MJ. Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes. Leukemia 2002; 16: 785–790. DOI: 10.1038/sj.leu.2402440
5. Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. The role of mesenchymal stem cells in hematopoiesis. Blood Rev 2006; 8: 315–317.
6. Poloni A, Leoni P, Buscemi L, Balducci F, Pasquini R, Masia MC et al. Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. Leukemia 2006; 20: 329–335. DOI: 10.1038/sj.leu.2404018
7. Geyh S, Oz S, Cadeddu RP, Fröbel J, Brückner B, Kündgen A et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013; 27: 1841–1851. DOI: 10.1038/leu.2013.193
8. Guerzoni C, Amatori S, Giorgi L, Manara MC, Landuzzi L et al. An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. BMC Cancer 2014; 14: 137. DOI: 10.1186/1471-2407-14-137
9. Wagner W, Bork S, Lepperdinger G, Joussen S, Ma N, Strunk D et al. How to track cellular aging of mesenchymal stromal cells? Aging (Albany NY) 2010; 2: 224–230. DOI: 10.18632/aging.100136
10. Poloni A, Maurizi G, Babini L, Serrani F, Berardinelli E, Mancini S et al. Human mesenchymal stem cells from chorionic villi and amniotic fluid are not susceptible to transformation after extensive in vitro expansion. Cell Transplant 2011; 20: 643–654. DOI: 10.3727/096368910X536518
11. Fanelli M, Caprodossi S, Ricci-Vitiani L, Porcellini A, Tomassoni-Ardori F, Amatori S et al. Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment. Oncogene 2008; 27: 358–365. DOI: 10.1038/sj.onc.1210642
12. Poloni A, Goteri G, Zizzi A, Serrani F, Trappolini S, Costantini B et al. Prognostic role of immunohistochemical analysis of 5 mc in myelodysplastic syndromes. Eur J Haematol 2013; 91: 219–227. DOI: 10.1111/ejh.12145
13. Romermann D, Hasemeier B, Metzing K, Schlegelberger B, Länger F, Kreipe H et al. Methylation status of LINE-1 sequences in patients with MDS or secondary AML. Verh Dtsch Ges Pathol 2007; 91: 338–342.
14. Pavlaki K, Pontikoglou CG, Demetriadou A, Batsali AK, Damianaki A, Simantirakis E et al. Impaired proliferative potential of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway. Stem Cells Dev 2014; 23: 1568–1581. DOI: 10.1089/scd.2013.0283
15. Medyouf H, Mossner M, Jann JC, Nolte F, Raffel S, Herrmann C et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell 2014; 14: 824–837. DOI: 10.1016/j.stem.2014.02.014